Bengaluru: Cytori Therapeutics  has received Japanese Patent No. 4722041 (the ‘041 patent) covering the preparation of adipose-derived stem and regenerative cell (ADRC) enriched fat grafts using any closed system, such as Cytori’s Celution® System. The patent specifically protects the Company’s cell-enriched fat grafting applications in Japan including breast reconstruction and other soft tissue defects, urinary incontinence and multiple cosmetic uses.

Cell-enriched fat grafting is the process of enriching the patient’s own fat tissue with their own stem and regenerative cells primarily for use in reconstructive and cosmetic procedures. Fat is taken from the patient’s stomach, hips, thighs, or other areas, by liposuction. Some of the tissue is used to extract the patient’s own stem and regenerative cells which occur naturally inside the tissue. The extracted cells are then combined with some of the patient’s own fat tissue, which forms a cell-enriched fat graft that is injected into the desired area.

This is Cytori’s second patent to be issued in Japan, in addition to Patent No. 4653952 covering devices for extracting and concentrating stem and regenerative cells from adipose tissue issued in February 2011. Cytori’s Japanese patents are a part of Cytori’s global intellectual property portfolio, including 34 issued patents and more than 100 pending applications.